Literature DB >> 22161383

Music therapy for people with schizophrenia and schizophrenia-like disorders.

Karin Mössler1, Xijing Chen, Tor Olav Heldal, Christian Gold.   

Abstract

BACKGROUND: Music therapy is a therapeutic method that uses musical interaction as a means of communication and expression. The aim of the therapy is to help people with serious mental disorders to develop relationships and to address issues they may not be able to using words alone.
OBJECTIVES: To review the effects of music therapy, or music therapy added to standard care, compared with 'placebo' therapy, standard care or no treatment for people with serious mental disorders such as schizophrenia. SEARCH
METHODS: We searched the Cochrane Schizophrenia Group Trials Register (December 2010) and supplemented this by contacting relevant study authors, handsearching of music therapy journals and manual searches of reference lists. SELECTION CRITERIA: All randomised controlled trials (RCTs) that compared music therapy with standard care, placebo therapy, or no treatment. DATA COLLECTION AND ANALYSIS: Studies were reliably selected, quality assessed and data extracted. We excluded data where more than 30% of participants in any group were lost to follow-up. We synthesised non-skewed continuous endpoint data from valid scales using a standardised mean difference (SMD). If statistical heterogeneity was found, we examined treatment 'dosage' and treatment approach as possible sources of heterogeneity. MAIN
RESULTS: We included eight studies (total 483 participants). These examined effects of music therapy over the short- to medium-term (one to four months), with treatment 'dosage' varying from seven to 78 sessions. Music therapy added to standard care was superior to standard care for global state (medium-term, 1 RCT, n = 72, RR 0.10 95% CI 0.03 to 0.31, NNT 2 95% CI 1.2 to 2.2). Continuous data identified good effects on negative symptoms (4 RCTs, n = 240, SMD average endpoint Scale for the Assessment of Negative Symptoms (SANS) -0.74 95% CI -1.00 to -0.47); general mental state (1 RCT, n = 69, SMD average endpoint Positive and Negative Symptoms Scale (PANSS) -0.36 95% CI -0.85 to 0.12; 2 RCTs, n=100, SMD average endpoint Brief Psychiatric Rating Scale (BPRS) -0.73 95% CI -1.16 to -0.31); depression (2 RCTs, n = 90, SMD average endpoint Self-Rating Depression Scale (SDS) -0.63 95% CI -1.06 to -0.21; 1 RCT, n = 30, SMD average endpoint Hamilton Depression Scale (Ham-D) -0.52 95% CI -1.25 to -0.21 ); and anxiety (1 RCT, n = 60, SMD average endpoint SAS -0.61 95% CI -1.13 to -0.09). Positive effects were also found for social functioning (1 RCT, n = 70, SMD average endpoint Social Disability Schedule for Inpatients (SDSI) score -0.78 95% CI -1.27 to -0.28). Furthermore, some aspects of cognitive functioning and behaviour seem to develop positively through music therapy. Effects, however, were inconsistent across studies and depended on the number of music therapy sessions as well as the quality of the music therapy provided. AUTHORS'
CONCLUSIONS: Music therapy as an addition to standard care helps people with schizophrenia to improve their global state, mental state (including negative symptoms) and social functioning if a sufficient number of music therapy sessions are provided by qualified music therapists. Further research should especially address the long-term effects of music therapy, dose-response relationships, as well as the relevance of outcomes measures in relation to music therapy.

Entities:  

Mesh:

Year:  2011        PMID: 22161383     DOI: 10.1002/14651858.CD004025.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  37 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Impaired musical ability in people with schizophrenia.

Authors:  Sanae Hatada; Ken Sawada; Masanori Akamatsu; Erina Doi; Masayoshi Minese; Motoshi Yamashita; Allen E Thornton; William G Honer; Shimpei Inoue
Journal:  J Psychiatry Neurosci       Date:  2014-03       Impact factor: 6.186

3.  Amusia and protolanguage impairments in schizophrenia.

Authors:  J T Kantrowitz; N Scaramello; A Jakubovitz; J M Lehrfeld; P Laukka; H A Elfenbein; G Silipo; D C Javitt
Journal:  Psychol Med       Date:  2014-03-31       Impact factor: 7.723

Review 4.  S3 guideline on psychosocial therapies in severe mental illness: evidence and recommendations.

Authors:  Uta Gühne; Stefan Weinmann; Katrin Arnold; Thomas Becker; Steffi G Riedel-Heller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-11-11       Impact factor: 5.270

Review 5.  Music therapy for people with schizophrenia and schizophrenia-like disorders.

Authors:  Monika Geretsegger; Karin A Mössler; Łucja Bieleninik; Xi-Jing Chen; Tor Olav Heldal; Christian Gold
Journal:  Cochrane Database Syst Rev       Date:  2017-05-29

6.  Yoga as part of a package of care versus non-standard care for schizophrenia.

Authors:  Julie Broderick; Davy Vancampfort
Journal:  Cochrane Database Syst Rev       Date:  2019-04-16

7.  Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.

Authors:  Daniel C Javitt
Journal:  Curr Treat Options Psychiatry       Date:  2015-06

8.  Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.

Authors:  Paolo Fusar-Poli; Evangelos Papanastasiou; Daniel Stahl; Matteo Rocchetti; William Carpenter; Sukhwinder Shergill; Philip McGuire
Journal:  Schizophr Bull       Date:  2014-12-20       Impact factor: 9.306

Review 9.  Music for insomnia in adults.

Authors:  Kira V Jespersen; Julian Koenig; Poul Jennum; Peter Vuust
Journal:  Cochrane Database Syst Rev       Date:  2015-08-13

Review 10.  A systematic review of music therapy practice and outcomes with acute adult psychiatric in-patients.

Authors:  Catherine Carr; Helen Odell-Miller; Stefan Priebe
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.